10-Q: Actuate Therapeutics Q1 2026 Results: Reduced R&D, Cash Concerns

Actuate Therapeutics reported a net loss of $5.6 million for Q1 2026, with a decrease in R&D spending and ongoing concerns about its ability to continue as a going concern beyond July 2026.

Summary

• Actuate Therapeutics reported a net loss of $5,625,749 for the first quarter ended March 31, 2026, compared to a net loss of $6,317,024 for the same period in 2025.
• Total operating expenses decreased to $5,705,956 from $6,365,584 in the prior year period, primarily driven by a reduction in research and development (R&D) expenses.
• R&D expenses decreased by $655,075 to $2,565,244, mainly due to lower external clinical study costs and CMC-related expenses, partially offset by increased nonclinical studies and personnel costs.
• General and administrative expenses remained relatively stable at $3,140,712 compared to $3,145,265 in the prior year, with an increase in personnel-related expenses offset by a decrease in professional and consulting fees.
• The company had cash and cash equivalents of $8,134,004 as of March 31, 2026, and anticipates that its current cash will not be sufficient to meet operational and capital requirements beyond July 2026 without raising additional capital.
• Actuate Therapeutics has an active At-the-Market (ATM) facility with approximately $99.5 million in remaining capacity and a Committed Equity Facility with $50 million in potential funding.
• The company presented updated Phase 2 data for elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC) showing a statistically significant improvement in median overall survival.
• An IND application was filed with the FDA for the oral tablet formulation of elraglusib, and FDA clearance was received to proceed with a Phase 1/2 clinical study.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant going concern warning and lack of revenue, despite positive clinical data and ongoing financing efforts.

Positives

• Positive updated data from the Phase 2 mPDAC study (Actuate-1801 Part 3B) showed a statistically significant improvement in median overall survival (mOS) with elraglusib/GnP versus GnP alone (10.1 months vs. 7.2 months, p=0.02, HR=0.62).
• The 12-month survival rate was nearly doubled in the elraglusib/GnP arm (44.4%) compared to the GnP arm (22.3%).
• The 24-month survival rate saw an almost fivefold increase in the elraglusib/GnP arm (12.9%) compared to the GnP control arm (2.6%).
• The safety profile of elraglusib has been well-tolerated in over 500 patients, suggesting potential for combination therapies.
• FDA clearance was received to proceed with a Phase 1/2 clinical study for the oral tablet formulation of elraglusib.
• An IND application was filed with the FDA for the oral tablet formulation of elraglusib.
• The company has approximately $99.5 million in remaining capacity under its At-the-Market (ATM) facility.

Negatives

• The company has substantial doubt regarding its ability to continue as a going concern, with current cash expected to last only until July 2026 without additional capital.
• Net loss for the quarter was $5,625,749.
• Accumulated deficit reached $160,233,450 as of March 31, 2026.
• The company has not generated any revenue from product sales.
• The company may be unable to raise sufficient capital on acceptable terms, which could force significant reductions in operations, including delaying or terminating product development or ceasing operations.
• There was a decrease in external clinical study expenses and CMC related costs, which, while reducing expenses, may indicate a slowdown in certain development activities.
• The company's ability to raise additional capital may be adversely impacted by market conditions.

Risks

• The company's ability to continue as a going concern is highly dependent on its ability to raise additional capital in the near term.
• If additional funding is not obtained, the company may need to significantly reduce its scope of operations, delay, limit, reduce, grant rights to develop, or terminate its product development, or even cease operations.
• The successful development of elraglusib is highly uncertain and subject to numerous factors including future study design, regulatory requirements, and potential future regulatory factors beyond the company's control.
• Future research and development expenses may vary significantly based on study results, patient costs, regulatory feedback, manufacturing costs, and changes in government regulation.
• The company's ability to raise additional capital may be adversely impacted by business conditions, global economic conditions, and volatility in financial markets.
• Raising additional capital through equity or convertible debt may dilute existing stockholders' ownership and could involve terms that adversely affect their rights.
• Debt or preferred equity financing may include covenants that limit the company's actions.
• Raising capital through collaborations or license agreements may require relinquishing valuable rights or granting unfavorable license terms.
• The exercise of warrants and stock options could dilute common stockholders' ownership.
• The June 2025 Private Placement Warrants expire 20 days following the FDA issuing Breakthrough Therapy Designation for elraglusib or providing written communication on pursuing registration with current Phase 2 data.

Future Outlook

Management anticipates that current cash and cash equivalents will not satisfy the Company's operational and capital requirements beyond July 2026 without raising additional capital. The company plans to seek financing through equity offerings, debt financings, or other capital sources. There is substantial doubt regarding the Company's ability to continue as a going concern.

Management Comments

• We believe that the blockade of GSK-3 signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.
• We believe elraglusib represents a pipeline in a molecule with a broad opportunity for us to potentially initiate and advance multiple drug development programs around our lead asset based on its multimodal mechanisms of action, data emerging from completed or ongoing clinical studies and nonclinical biological, cellular, and animal data.
• We believe that we can further improve the outcome of patients using the Elraglusib Oral Tablet at the RP2D, including a more frequent dosing regimen to be identified in the Phase 1 study.
• In addition, the safety profile of elraglusib in over 500 patients to date shows the product is well tolerated as a monotherapy and in combination with chemotherapy.
• We expect to continue to incur significant expenses and operating losses in the foreseeable future as we advance the clinical development of elraglusib and any future product candidates.

Industry Context

StockSavvy.ai notes that Actuate Therapeutics operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector. The company's focus on GSK-3 inhibition for cancer treatment places it in a niche with potential for significant therapeutic impact, but also high development risk. The reliance on external financing, common in this industry, is a critical factor for continued operations and advancement of its lead candidate, elraglusib.

Comparison to Industry Standards

• The net loss per share of $(0.24) for Q1 2026 is within the typical range for clinical-stage biopharmaceutical companies that are pre-revenue and investing heavily in R&D.
• The decrease in R&D spending by approximately 20% compared to the prior year period, while reducing immediate cash burn, could be viewed cautiously if it signifies a slowdown in critical development milestones, though the company cites specific reasons like reduced patient fees and timing of manufacturing.
• The company's cash runway extending only to July 2026 without additional funding is a common concern for companies at this stage, highlighting the industry's reliance on continuous capital infusion through equity markets or strategic partnerships.
• The successful presentation of statistically significant survival data in mPDAC is a positive indicator, aligning with industry benchmarks for advancing drug candidates towards later-stage trials and potential regulatory approval.

Legal Proceedings

• To the Company's knowledge, the Company is not subject to any ongoing or pending legal proceedings.

Related Party Transactions

• Dr. Aaron G.L. Fletcher, Chairman of the Board, is a Managing Partner and co-founder of Bios Partners, an affiliate of Bios 2024 Co-Invest, LP, which was an investor in the June 2025 private placement. Warrants were issued to purchase up to 666,497 shares of common stock at an exercise price of $7.00 per share in this private placement.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, but also potential upside if elraglusib development is successful. Current cash concerns create uncertainty.
• Employees: Continued employment depends on securing additional funding; stock-based compensation is a significant expense.
• Creditors: No significant debt mentioned, but the going concern status could impact future credit availability.
• Licensors (UIC): Continued royalty and milestone payments are contingent on future commercial success and specific financing events.

Next Steps

• Advance the oral tablet formulation of elraglusib into a Phase 1/2 clinical study to identify the maximum tolerated dose and Recommended Phase 2 Dose (RP2D).
• Pursue further clinical development of Elraglusib Oral Tablet in indications such as first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), refractory metastatic melanoma, refractory metastatic colorectal cancer, and non-small cell lung cancer, subject to additional funding.
• Continue development of Elraglusib Injection in pediatric cancer patients, potentially for Ewing sarcoma and neuroblastoma, pending additional funding.
• Seek financing for operations through equity offerings, debt financings, or other capital sources to extend cash runway beyond July 2026.
• Engage with regulatory authorities (FDA, EMA) regarding clinical study designs and feedback in 2026.

Key Dates

Recommendation

Actuate Therapeutics presents a mixed picture. The positive clinical data for elraglusib in mPDAC is a significant development, and the FDA clearance for the oral formulation is promising. However, the severe going concern warning, with cash projected to last only until July 2026 without additional funding, introduces substantial risk. The company has access to capital through ATM and equity facilities, but their effectiveness and terms are uncertain. Given the high risk associated with the going concern issue, balanced against the potential of the drug candidate, a 'hold' recommendation is appropriate for seasoned investors who can tolerate the risk and await further financing developments or clinical progress.

Keywords

Actuate Therapeutics, 10-Q, Quarterly Report, elraglusib, GSK-3 inhibitor, biopharmaceutical, clinical-stage, cancer therapy, pancreatic cancer, metastatic pancreatic ductal adenocarcinoma, mPDAC, FDA, IND application, going concern, capital raise, ATM facility, Committed Equity Facility, stock-based compensation, net loss, R&D expenses